University of Edinburgh EASTBIO PhD: Human CYP Reporter Hepatocytes for Environmental and Dietary Chemical Screening

University of Edinburgh EASTBIO PhD: Human CYP Reporter Hepatocytes for Environmental and Dietary Chemical Screening

Research Question and Fit

This Edinburgh project combines expandable human hepatocyte models with image-based screening to investigate how environmental and dietary xenobiotics affect metabolism. The distinctive training opportunity lies between cell-model development and assay validity: a fluorescent reporter must say something reliable about a human metabolic response, not merely produce a convenient signal. Kaji's regenerative-medicine expertise and Carragher's phenotypic-screening experience are complementary.

Four-year EASTBIO competition funding explicitly covers maintenance and full international tuition through Edinburgh's fee-gap contribution. The deadline is 16 November 2026, with no clock or time zone stated. Send the EASTBIO form and PDF transcripts to IRRSchoolPGR@ed.ac.uk; template references must reach the same address by the deadline. The principal uncertainties are readiness of the new reporter system, its relationship to enzyme activity, and the exact registered programme. The advert's OECD “draft” wording also needs updating against the published July 2026 guideline.

Research Problem and Doctoral Work

Human hepatocytes metabolise endogenous substances and xenobiotics. Changes in CYP expression and activity can alter metabolism, but induction alone does not determine whether a substance is safe or harmful in a person. The project focuses on CYP3A4, CYP1A2 and CYP2B6; CAR is part of the regulatory background associated with CYP2B6.

Primary human hepatocytes are a valuable reference but have supply, cost and donor/batch-variation constraints. The advert describes a precursor state, pre-cHep, and differentiated cHep cells. It attributes expansion of more than a million-fold within 30 days and liver-repopulation capacity to earlier work, and describes cHep expression and inducibility as comparable to three-dimensional primary human hepatocyte cultures. Those are claims about the prior cell platform, not validated performance of this proposed reporter system. The available record for the 2026 preprint and earlier conference presentation is bibliographic only; it does not independently verify the advertised expansion and repopulation performance.

The proposed doctoral work connects human reporter-cell models, response assessment and quantitative screening of chemical collections. Its central evidential question is whether an accessible fluorescent signal reliably represents the metabolic response of interest. Transcriptional reporting, functional enzyme activity and a broader adverse biological outcome are distinct endpoints. A fluorescence change could also reflect cell state, growth, viability or optical interference. Agreement with independent functional measurements and suitable reference models therefore matters more than screen size alone. Donor coverage, stability of the mature phenotype and reproducibility across batches define the eventual applicability domain.

The regulatory context is more current than the advert suggests. OECD consulted on a draft in November–December 2025, then published Test No. 445A on 2 July 2026, DOI 10.1787/765aaada-en. It addresses CYP induction using metabolically competent human hepatic systems and enzyme-activity endpoints; CYP2B6 is discussed with less certainty. A new fluorescent reporter is not automatically equivalent to that endpoint or already accepted under the guideline. Nor does publication establish a universal legal requirement for every company to screen every chemical variant. Regulatory relevance is real, but method validation and jurisdiction-specific acceptance remain separate questions.

Useful outcomes could include a transparent account of model reliability, an interpretable screening readout and evidence identifying where reporter and functional responses agree or diverge. These are prospective contributions. “Non-animal platform” describes the intended in-vitro screening use, not a demonstrated claim that every stage of prior development was animal-free. The project does not establish clinical treatment, drug-interaction or dietary-supplement safety advice.

School, Programme and Field Context

The University of Edinburgh awards the degree; the advertised host is the School of Regeneration and Repair, College of Medicine and Veterinary Medicine. Kaji's group is based in the Centre for Regenerative Medicine within IRR. Carragher's current institutional home includes the Institute/School of Genetics and Cancer. Cross-unit supervision is an internal Edinburgh arrangement; the formal registered programme still needs confirmation.

The current 2027 Regenerative Medicine PhD, course-page identifier 695, is a relevant comparator: it belongs to the same School and CRM/IRR and uses IRRSchoolPGR@ed.ac.uk. It lists an ordinary three-year full-time PhD. The exact registered award name/code and four-year arrangement for this studentship remain unconfirmed. The ordinary course duration must not replace the advertised four-year EASTBIO funding framework.

The programme describes seminars, journal clubs, presentations, supervisory training and specialist facility support. Imaging, flow cytometry, high-content screening, biomolecular analysis, single-cell methods and statistics form an interdisciplinary environment; personal access and staff support need agreement. EASTBIO's framework for cohorts from 2025 places core training in years one and two, with research emphasised in years three and four. Its current calendar is not a promised personal 2027 timetable. The advert does not identify a CASE partner or fixed industrial placement duration.

Edinburgh reports 35th overall in QS 2027 and fourth in UK research power in REF 2021. These are institutional signals rather than a rank for the hepatocyte group or this specific degree. Relevant strength is better judged from the complementary cell-model and screening research, facilities and supervision. A project-specific laboratory ranking or verified graduate-placement rate was not established.

Supervisor and Lab Assessment

Professor Keisuke Kaji, group leader in regenerative medicine, lists keisuke.kaji@ed.ac.uk and 0131 651 9551 as public contacts. His current group focuses on pre-cHep/cHep use in toxicology, screening and disease models. Professor Neil O Carragher is Professor/Personal Chair of Drug Discovery and, from 2024, Director of Science, Edinburgh Cancer Research; his professional email is n.carragher@ed.ac.uk. His profile dates the separate Director of Translation role to 2018–2024, so older pages should not establish that as his current post.

Carragher's laboratory describes high-content and kinetic imaging, automated handling and data integration. These support screening expertise but do not guarantee a student instrument slot, an available compound library or liver-specific validation. Kaji's current grants show active translation, but several end before a likely 2027 PhD start. They must not be counted as the individual's award. The division of model development, assay analysis and day-to-day mentoring needs clarification.

Three genuine recent peer-reviewed originals inform the assessment:

Cell-state transitions and stable function

Ozkan et al., Nature Communications 16:8647, 30 September 2025, DOI 10.1038/s41467-025-63806-3; Kaji coauthor. The study distinguishes context-dependent roles in changing cell identity from maintaining an established cell state. The available evidence includes the complete institutional abstract, author contributions and selected original-indexed results/discussion. It shows why an expandable state and a stable differentiated function require different evidence. It is not a CYP-reporter or hepatocyte-validation study; the available material does not include the complete paper, supplements or replication data.

Screening data and biological generalisation

Smer-Barreto et al., Nature Communications 14:3445, 10 June 2023, DOI 10.1038/s41467-023-39120-1; Carragher coauthor. The available evidence includes the complete PubMed abstract and original indexed data-assembly, results and statistical-method passages. The work connects literature-derived training data to cell-based validation. Assumed negative labels, heterogeneous experiments and transfer between biological contexts limit interpretation. This supports screening/data expertise, not CYP-induction accuracy or clinical benefit. The full methods and supplements are not represented in the available material.

Three-dimensional imaging and benchmarking

Lee et al., SLAS Discovery, advance online 14 August 2026, DOI 10.1016/j.slasd.2026.100329; Carragher corresponding author. The available evidence includes the complete original institutional abstract and publication record. A dual-view oblique-plane microscopy platform is benchmarked against conventional two- and three-dimensional assays and captures single-cell heterogeneity within tumour spheroids. It provides relevant experience in assay benchmarking and quantitative three-dimensional imaging. It concerns glioblastoma models, not hepatocytes or this new reporter; complete methods, results and supplements are not represented in the available material.

These papers provide adjacent evidence on cell-state, screening-data and three-dimensional-imaging research; none validates the proposed CYP reporter platform. The available 2026 pre-cHep preprint record is bibliographic only and does not independently verify the earlier cell-platform performance claims.

Funding, Application, and Living Cost

The specific advert states four-year EASTBIO competition funding, maintenance and Home tuition, with Edinburgh paying the international fee difference for appointees. This provides a positive full-fee and living-support route for eligible Chinese and other international candidates. EASTBIO's 30% annual international-intake cap is a partnership constraint, not an individual admission probability or this project's international seat count. Not already having a personal award is not a reason to postpone an application.

The £21,805 UKRI minimum is a 2026–27 reference, not a confirmed 2027 personal rate. Clarify the payment schedule, research support, functional-validation and facility costs, and continuation charges. The related course warns that additional research costs depend on the project and funding scheme; its generic estimates are not a personal invoice. Research support is not disposable maintenance income.

Use the project's IRRSchoolPGR@ed.ac.uk email route for the EASTBIO form and PDF transcripts. Two references must use the EASTBIO template and arrive at that address by 16 November 2026. Complete the anonymous EDI survey and enter its unique identifier on the form. Only one project application is allowed across EASTBIO, and prospective project supervisors cannot provide references. Later formal admission may request qualifications, translations and English evidence; it does not replace the advertised initial submission.

EASTBIO's general framework points to 1 October 2027, but the advert does not confirm this student's exact start. The saved complete recruitment text gives this project a specific application route; its future deadline does not independently confirm current availability.

Edinburgh's official 2026–27 single-postgraduate estimate, calculated in March 2026, is £1,542 per month or £18,504 over 52 weeks, including £978 monthly accommodation/utilities. Compared with the same year's minimum stipend, that leaves an illustrative £3,301 before excluded costs or personal differences. It is not guaranteed savings, a family budget or a 2027 quotation. Costs also depend on the commute to the research location.

EASTBIO excludes visa and IHS charges. The saved government fee references are £558 for a Student visa application and £776 per student visa year for IHS, with duration/part-year rules; future prices may change. Flights, deposits and initial cash before the first stipend payment should be budgeted separately. Confirm which research and professional-placement travel costs the individual award covers.

Applicant Fit and Preparation

The advert promises training in human-cell research, reporter methods and image-based high-throughput analysis but does not impose a named technique checklist or a specific degree background. EASTBIO's baseline is a UK 2:1 or international equivalent; a Master's is not compulsory. When the undergraduate 2:1-equivalent threshold is not met, a Master’s degree (or equivalent) or significant relevant professional experience may support consideration for assessment. Cell biology, biochemistry, pharmacology, toxicology and quantitative bioscience are reasonable backgrounds to discuss, not newly imposed subject requirements.

Chinese qualifications have a positive recognised-university/Priority List route in Edinburgh's official guidance, combined with EASTBIO's explicit international eligibility. The 80% / 80–85% table covers taught courses and two named MScR programmes, not a confirmed threshold for this PhD. Ask the relevant admissions team to assess the actual institution, transcript and subject rather than importing that table or requiring a Master's for everyone.

If the relevant 2027 Regenerative Medicine course is confirmed, its English reference is IELTS 6.5 overall, 6.0 each; TOEFL before 21 January 2026: 92 overall, 23 each, and on/after that date 4.5 overall, 4.5 each. It excludes IELTS One Skill Retake and TOEFL MyBest. IELTS/TOEFL normally must be no more than two years old on the first day of the start month. English-medium degrees are assessed under approved-country/university and age rules; Chinese English-medium study is not automatically exempt. These are that relevant course's conditions, not a confirmed individual offer or borrowed Biology requirement.

Useful preparation would show reproducible analysis, awareness of biological variation and a clear distinction between reporter expression, enzyme function and an adverse outcome. A discussion of model applicability and assay uncertainty is more useful than treating fluorescence as a direct safety verdict. These are analyst suggestions, not extra compulsory documents or a laboratory protocol.

Career and Transferable Skills

Skills can transfer into bioscience screening, toxicology and quantitative assay research, but no job, salary, clinical accreditation or industrial placement is guaranteed by the available evidence.

Next Actions and Questions to Verify

Before applying: confirm the deadline clock/time zone and email-document workflow with IRR administration; ask for the exact registered programme, four-year arrangement, Chinese qualification assessment and English conditions. Discuss model availability and the balance of cellular versus computational work with Kaji and Carragher.

At interview: ask what evidence supports the prior pre-cHep/cHep performance, which new reporter capabilities remain to be established, and how reporter responses will be related to independent functional evidence. Clarify donor coverage, batch/state stability, optical interference, applicability limits and daily mentorship. Discuss the published OECD guideline's relevance without presuming regulatory acceptance.

Before accepting: verify full international tuition and maintenance coverage, the 2027 rate, research/facility costs, placement arrangements and any continuation costs. Agree supervision, access to data and facilities, publication arrangements, housing and arrival cash. Student visa sponsorship requires CAS and individual eligibility; ATAS depends on the actual registered research classification. Chinese nationality is not an admission exclusion but is not exempt if a covered subject requires ATAS.

Evidence and Sources

Project context, supervisors and scientific evidence

• Keisuke Kaji current regenerative medicine research group

• Neil Carragher current Drug Discovery Chair and Science Director

• Kaji current publication and active grant record

• OECD published Test 445A CYP induction in differentiated human hepatic cells

• OECD 2025 CYP guideline consultation historical version

• Pre-cHep 2026 original preprint bibliographic record only

• Ozkan et al. 2025 cell-type-specific OCT4 functionality original

• Smer-Barreto et al. 2023 machine-learning senolytic discovery original

• Lee et al. 2026 dOPM three-dimensional phenotypic screening original

• Regenerative Medicine 2027 IRR programme, China and English — relevant route comparator

• Edinburgh QS 2027 overall ranking

Funding, training, eligibility and budget

• EASTBIO current international fee-waiver and funding FAQ

• EastBio 2027 how to apply

• EastBio selection process

• EastBio training overview

• China postgraduate qualification equivalencies

• Edinburgh 2026/27 postgraduate living budget

• UKRI current stipend reference

Immigration and careers

• UK Student visa route and current fees

• UK student immigration healthcare charge

• ATAS nationality and covered subject rules

• Royal Society Biology careers resources